Microtubule Inhibition Triggers MYC-Mediated Immunogenic Cell Death in Breast Cancer
Authors:
- Ruixian LiuRLRuixian Liu
- July AungJAJuly Aung
- Aino PeuraAPAino Peura
- Antti O HiltunenAHAntti O Hiltunen
- Linda IdLILinda Id
- Mariel SaveliusMSMariel Savelius
- Martina PeltonenMPMartina Peltonen
- Rita TurpinRTRita Turpin
- Natasha SalmelinNSNatasha Salmelin
- Johanna M AnttilaJAJohanna M Anttila
- Topi A TervonenTTTopi A Tervonen
- Ilida SuleymanovaISIlida Suleymanova
Preprint
Abstract
Oncogenic MYC promotes cancer cell proliferation, metabolism, and death, while also driving immunosuppression in the tumour microenvironment, complicating immune-based therapies. To counter MYC-driven immune evasion while leveraging MYC-dependent synthetic lethality (MYC-SL), we identified microtubule-targeting agents, including eribulin, as potent inducers of immunogenic cell death in MYC high triple-negative breast cancer (TNBC). A screen of 528 oncology compounds using damage-associated molecular pattern (DAMP) reporters revealed that microtubule inhibitors induced key DAMPs, including HMGB1 secretion, calreticulin exposure, and double-stranded DNA release, leading to gasdermin-E associated cell death in MYC high TNBCs. Immune cell co-culture assays showed immune activation, and patient-derived explant cultures confirmed pro-inflammatory cytokine responses. In vivo, cell-free media from eribulin-treated MYC high murine TNBCs enhanced tumour protection in vaccination models compared to MYC-knockdown controls, linking MYC-dependent DAMP release to immunogenicity. These findings highlight a dual-function therapeutic strategy: agents that selectively induce MYC-dependent immunogenic cell death can provide both targeted cytotoxicity and local immune stimulation, thereby addressing a key limitation of conventional chemotherapeutics, offering a new approach for MYC-driven cancers.Keywords
Funding Information
- Academy of Finland https://ror.org/05k73zm37 (350393)
- Business Finland https://ror.org/05bgf9v38 (2141/31/2019)
- Cancer Society of Finland https://ror.org/05pgg4z49
- Sigrid Jusélius Foundation https://ror.org/00ckakm23 (240095)
- Jane and Aatos Erkko Foundation https://ror.org/03vxy9y38 (200035)
- European Unions Horizon 2020 (847912)
- Department of Defence, Breast Cancer Research Program (CDMRP W81XWH211-0773/-0774)
- iCAN - Digital Precision Cancer Medicine Flagship
- Finnish Red Cross Blood Service Research Fund
This publication has 53 references indexed in Scilit:
- Functional and clinical roles of stromal PDGF receptors in tumor biologyCancer and Metastasis Reviews, 2024
- The Coming Decade of Cell Death Research: Five RiddlesCell, 2019
- Myc Cooperates with Ras by Programming Inflammation and Immune SuppressionCell, 2017
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsCancer Cell, 2015
- MYC Is a Major Determinant of Mitotic Cell FateCancer Cell, 2015
- The Mechanism of Phagocytosis: Two Stages of EngulfmentBiophysical Journal, 2014
- MYC on the Path to CancerCell, 2012
- Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapyImmunologic Research, 2011
- c‐Myc‐dependent etoposide‐induced apoptosis involves activation of Bax and caspases, and PKCdelta signalingJournal of Cellular Biochemistry, 2006
- Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progressionInternational Journal of Cancer, 1999